Coronary Flow Reserve and Glucometabolic State
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Diabetes mellitus is a major risk factor for the development of ischemic heart disease, and patients with diabetes mellitus have a worse outcome following an acute myocardial infarction than non-diabetic patients. Furthermore, abnormal glucose metabolism below the diagnostic threshold of diabetes mellitus is also associated with increased risk of death compared to patients with a normal glucose metabolism. The frequency of abnormal glucose metabolism in acute myocardial infarction is high, and approximately 70% of myocardial infarction patients have diabetes mellitus, newly diagnosed diabetes mellitus or impaired glucose tolerance, leaving only 30% with normal glucose metabolism. The increased mortality among patients with acute myocardial infarction and abnormal glucose metabolism seems mainly related to a higher occurrence of congestive heart failure, suggesting that an abnormal glucose metabolism may play an important role among others in endothelial dysfunction, infarct healing and overall left ventricle function. This raises the question, whether patients with acute myocardial infarction and abnormal glucose metabolism have increased frequency of micro- or macrovascular disease or both.
Coronary flow velocity reserve reflects the patency of the epicardial coronary artery in combination with vasodilator capacity of the microcirculation and may therefore offer a tool for assessment of macro- and microcirculation.
This study will focus on the relation between coronary flow velocity reserve estimated by transthoracal Doppler echocardiography and mortality, risk for heart failure and left ventricle function after acute myocardial infarction stratified according to glycometabolic state
| Condition |
|---|
|
Acute Myocardial Infarction Diabetes Mellitus Prediabetes |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Coronary Flow Velocity Reserve According to Glucometabolic State in Acute Myocardial Infarction; Relation to Ventricular Systolic and Diastolic Function |
| Enrollment: | 190 |
| Study Start Date: | January 2006 |
| Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| No treatment |
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients suffering from a acute myocardial infarction
Inclusion Criteria:
- Newly diagnosed first AMI based on characteristic clinical symptoms and/or electrocardiographic signs of AMI and Troponin T or I or CK-MB over diagnostic limits for AMI
- Referral for coronary arteriography based on the actual myocardial infarction
- Written informed consent
Exclusion Criteria:
- Previous myocardial infarction
- Asthma bronchiale
- 2 or/and 3 degree atrio-ventricular block and paced rhythm
- Mental state that makes the patient unavailable in attending the study
- Use of dipyridamol
- Sick Sinus Syndrome
Contacts and Locations
More Information
No publications provided by Medicinsk Forsknings Afdeling
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Brian Bridal Løgstrup, Medicinsk Forskning Afdeling |
| ClinicalTrials.gov Identifier: | NCT00845468 History of Changes |
| Other Study ID Numbers: | 07-4-B368-A1392-22379, VF 20050103 |
| Study First Received: | February 17, 2009 |
| Last Updated: | February 17, 2009 |
| Health Authority: | Denmark: Regional Ethics Committee of Southern Denmark Denmark: Danish Dataprotection Agency |
Keywords provided by Medicinsk Forsknings Afdeling:
|
coronary flow reserve diabetes mellitus acute myocardial infarction transthoracic echocardiography |
Additional relevant MeSH terms:
|
Diabetes Mellitus Infarction Myocardial Infarction Glucose Intolerance Prediabetic State Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Ischemia Pathologic Processes Necrosis Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases Hyperglycemia |
ClinicalTrials.gov processed this record on June 18, 2013